Neal D. Shore, MD

Carolina Urologic Research Center

Myrtle Beach, South Carolina

Dr. Neal Shore graduated from both Duke University and Duke University Medical School. He completed his general surgery/urology residency at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He is the Medical Director for the Carolina Urologic Research Center and he practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 400 clinical trials, focusing mainly on GU Oncology indications. He is the Chief Medical Officer, Surgery/Urology, for GenesisCare, US. He has more than 250 peer-reviewed publications and numerous book chapters. Dr. Shore serves on the SITC Guidelines Committee for Bladder Cancer as well as the boards of the Bladder Cancer Advocacy Network and the Duke Global Health Institute. He is the Chair of the LUGPA Education Committee. He is on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, World Journal of Urology, and also serves as Editor, Everyday Urology-Oncology. He is a Fellow of the American College of Surgeons.

Disclosures:

Dr. Shore has the following disclosures:
- Advisory Committee Member: Amgen, Astellas, Bayer, Dendreon, Ferring, Janssen, Merck, Pfizer, Sanofi, Tolmar
- Consultant: Amgen, Astellas, Bayer, Dendreon, Ferring, Janssen, Merck, Pfizer, Sanofi, Tolmar

Talks by Neal D. Shore, MD

29 MHz High Resolution Micro-Ultrasound: Improving Real-Time Targeting of Prostate Biopsies

Posted by Neal D. Shore, MD | Mar 2019

Neal D. Shore, MD, reviews a novel 29 MHz high-resolution micro-ultrasound system with improved visualization for prostate biopsy compared to the current standard. He also provides a brief overview of current clinical evidence for this technology.

Navigating the M0 Space- Results of RADAR III

Posted by Neal D. Shore, MD | Mar 2019

Neal D. Shore, MD, reviews the recently-published guidelines focused on next generation imaging for early detection of disease progression in M0 prostate cancer in the Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence III (RADAR III). He also reviews the goals and conclusions from RADAR I and II.

A Novel Micro-Ultrasound System for Improving Transrectal Prostate Biopsy

Posted by Neal D. Shore, MD | Nov 2018

Neal D. Shore, MD, introduces a real-time high resolution micro-ultrasound system for calculating prostate malignancy risk levels and guiding prostate biopsies. He also compares accuracy and practical benefits of micro-ultrasound to conventional ultrasound and MRI-guided biopsy techniques.

A Primer on Alternative Payment Models: The Need for a Urology APM

Posted by Neal D. Shore, MD | Apr 2018

Neal D. Shore, MD, FACS, summarizes how the Large Urology Group Practice Association (LUGPA) has and continues to preserve and advance the independent practice of urology by healthcare policy advocacy, business and administrative excellence, clinical and therapeutic education, and ensuring the success of future leaders through their Young LUGPA program.

The Present and Future of LUGPA